Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
NCT ID: NCT06300203
Last Updated: 2025-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2024-03-18
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
NCT05470647
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
NCT06028490
Study of CM310 in Subjects With Seasonal Allergic Rhinitis
NCT06171074
Study of CM310 in Subjects With Allergic Rhinitis
NCT05908032
Effect and Underlying Immunological Mechanisms of Sublingual Immunotherapy in Allergic Rhinitis
NCT03649139
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
AR has a variety of classification methods. According to the type of allergen, it can be divided into seasonal (SAR, common allergens are seasonal allergens such as pollen) and perennial (PAR, common allergens are indoor allergens such as dust mites or occupational allergies), which is a classification method often used in clinical studies. According to the course of the disease, it can be divided into intermittent (symptom onset \< 4 days/week, or \< 4 consecutive weeks) and persistent (symptom onset ≥ 4 days/week, and ≥ 4 consecutive weeks). According to the severity of the disease, it can be divided into minor AR (mild symptoms, with no significant impact on quality of life) and moderate-severe AR (more severe or severe symptoms, with significant impact on quality of life). The results of the cooperative survey showed that persistent moderate-to-severe disease was the most common in the overall population, accounting for 52.2%, indicating that the treatment and control of AR has become an urgent problem to be solved.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interleukin-4 receptor responders
Interleukin-4 receptor was injected subcutaneously.
Interleukin-4 receptor responders
Interleukin-4 receptor was injected subcutaneously.
Placebo
Placebo was injected subcutaneously.
Placebo
Placebo was injected subcutaneously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interleukin-4 receptor responders
Interleukin-4 receptor was injected subcutaneously.
Placebo
Placebo was injected subcutaneously.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Tongren Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luo Zhang
Role: STUDY_CHAIR
Beijing Tong-Ren hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM310_IIS_SAR07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.